Novo Nordisk, UniQure, XLV in focus for biotech

Novo Nordisk is the biggest near-term catalyst. The Danish drugmaker holds its 2026 Capital Markets Day in London on Monday as it tries to broaden investor focus beyond semaglutide, the active ingredient behind Ozempic and Wegovy, and toward a pipeline that includes the experimental obesity drug CagriSema, slated for 2027. The event comes as competition with Eli Lilly intensifies, and investors will be watching for any update on how Novo intends to defend its franchise and regain momentum after a run of heavy expectations in obesity and diabetes.

The readout calendar also turns busy. UniQure is due by quarter-end to provide a four-year update from its Phase 1/2 AMT-130 study in Huntington’s disease, after already filing its biologics license application using three-year data and an external control. That makes the update a potentially important de-risking event for one of the sector’s most closely watched gene therapy programs. Scynexis is also guiding to third-quarter Phase 1 results for IV SCY-247, an antifungal aimed at invasive candidiasis and prevention of invasive fungal disease, giving investors another data point on whether small-cap clinical assets can still attract capital.

Policy risk sits in the background. The Senate Health, Education, Labor and Pensions Committee is scheduled to hear Heidi Overton’s nomination to lead the FDA on Thursday, and any shift in the agency’s leadership could affect drug review timing, clinical-trial policy and the broader regulatory tone for biotech approvals.

The IPO window is reopening, but not without friction. Electra Therapeutics begins its first full week of trading after raising $350 million at $25 a share, only to close its debut 12% below the offer price. Two more names, Retension Pharmaceuticals and TRex Bio, filed for U.S. listings on Friday, with Eli Lilly planning to invest in TRex alongside the offering. For investors, that mix points to selective demand rather than a blanket return to risk, even as the sector’s biggest themes — obesity, gene therapy and immunology — keep drawing capital.

The next trade in biotech will likely depend on whether scientific updates can offset policy uncertainty and weak debut performance. If Novo’s strategy update lands well and UniQure’s data hold up, the sector could extend its lead; if not, investors may rotate back toward the larger, profitable healthcare names already propping up XLV.